.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Teva
Colorcon
Novartis
Healthtrust
Daiichi Sankyo
Chubb
QuintilesIMS
Baxter

Generated: September 19, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Heteroaryl N-hydroxy amides and ureas with polar substituents as 5-lipoxygenase inhibitors
Abstract:Compounds, compositions a method of inhibiting lipoxygenase and treating related disorders are disclosed. The compounds are of the formula: wherein Ar is ##STR1## where X is O, S, SO.sub.2 or NR.sub.3 ; R.sub.3 is hydrogen, alkyl, alkylaryl, alkoyl, alkylakoyl, aroyl or alkylaroyl; Y is hydrogen, halogen, alkyl, alkenyl, cycloalkyl, aryl, arylalkyl, arylalkenyl, --OR, --SR, --COOR, --COR, --CON(R).sub.2, --OCOR, --N(R).sub.2, --O(CH).sub.2, --SO.sub.2 R, --SO.sub.2 N(R).sub.2, --O(CH.sub.2).sub.p OR, --CN, --NO.sub.2, --O(CH).sub.p O(CH.sub.2).sub.p OR or --CF.sub.3 ; R is hydrogen, hydroxyl, alkyl, alkylaryl or aryl; m is 0 to 5; p is 1 to 4; A is C.sub.1 -C.sub.12 alkylene or C.sub.2 -C.sub.14 alkenylene; R.sub.2 is --OR, --SR, --COOR, --COR, --CON(R).sub.2, --OCOR, --N(R).sub.2, --O(CH.sub.2).sub.y CON(R).sub.2, --O(CH.sub.2).sup.y OR, --CN, --NO.sub.2, 1-tetrazolo, C.sub.4 -C.sub.8 cyclic amido, imidazolo, --O(CH.sub.2).sub.y O(CH.sub.2).sub.y OR, --CF.sub.3, --N(R) COCHR--NH(R), CONHCH(R)CO.sub.2 R, --OCOCHR-NH(R), --CR(NHR)CONR, --CR(NHR)COR, morpholino, --NH(CH.sub.2).sub.y OH, --N[(CH.sub.2).sub.y OH].sub.2, --N.sub.3, --SO.sub.2 N(R).sub.2, --N(R)COR, --N(R)COOR, --N(R)CON(R).sub.2, --C(.dbd.NOH)NHOH or --C(.dbd.NOH)NH.sub.2 where R is as defined above, y is 1 to 4 and --N(R).sub.2 can form a heterocyclic ring of 5-8 atoms; M is hydrogen, a pharmaceutically acceptable cation or a metabolically cleavable group; Z is oxygen or sulfur; and R.sub.1 us hydrogen, alkyl, alkenyl, --NR.sub.4 R.sub.5, --NCOR.sub.6 or --Q--(R.sub.2).sub.2 where R.sub.4 and R.sub.5 independently selected from the group consisting of hydrogen, hydroxyl, alkyl, substituted alkyl with 1-3 substituents selected from the group consisting of R.sub.2 as defined above, acyl, aryl and CON(R).sub.2 is as defined above, R.sub.6 is hydrogen alkyl, alkylaryl, aryl or NR.sub.4 R.sub.5 where R.sub.4 and R.sub.5 are as defined above and where NR.sub.4 R.sub.5 can form a heterocyclic ring of a 5-8 atoms, Q is alkyl, alkenyl or aryl and z is 0 to 3; provided when n is O, R.sub.1 is not hydrogen, alkyl, alkenyl, or NR.sub.4 R.sub.5 wherein R.sub.4 and R.sub.5 are as defined above; and the pharmaceutically acceptable salts thereof.
Inventor(s): Brooks; Dee W. (Libertyville, IL), Summers; James B. (Libertyville, IL), Rodriques; Karen E. (Grayslake, IL), Maki; Robert G. (Kenosha, WI), Dellaria; Joseph F. (Lindenhurst, IL), Holms; James H. (Gurnee, IL), Moore; Jimmie L. (Gurnee, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Filing Date:Nov 01, 1989
Application Number:07/430,710
Claims:1. A compound having the formula ##STR81## wherein A is alkylene of from one to twelve carbon atoms or alkenylene of from two to fourteen carbon atoms;

M is selected from the group consisting of

hydrogen,

a pharmaceutically acceptable cation, and

a metabolically cleavable group;

R.sup.7 is selected from the group consisting of

hydroxyl substituted alkyl of from one to twelve carbon atoms,

carboxyl substituted alkyl of from one to twelve carbon atoms and the pharmaceutically acceptable acid addition salts thereof, and

ethoxycarbonyl substituted alkyl of from one to twelve carbon atoms.

2. A pharmaceutical composition for inhibiting lipoxygenase activity in a mammal in need of such treatment comprising a pharmaceutical carrier and a therapeutically effective amount of a compound of claim 1.

3. A method for inhibiting lipoxygenase activity in a mammal in need of such treatment comprising administering to the mammal a therapeutically effective amount of a compound of claim 1.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Merck
Harvard Business School
Chubb
Johnson and Johnson
Cipla
Cerilliant
Julphar
Novartis
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot